61 related articles for article (PubMed ID: 24981506)
1. Addressing barriers and identifying facilitators to support informed consent and recruitment in the Cavernous malformations A Randomised Effectiveness (CARE) pilot phase trial: insights from the integrated QuinteT recruitment intervention (QRI).
Wade J; Farrar N; Realpe AX; Donovan JL; Forsyth L; Harkness KA; Hutchinson PJA; Kitchen N; Lewis SC; Loan JJM; Stephen J; Al-Shahi Salman R;
EClinicalMedicine; 2024 May; 71():102557. PubMed ID: 38813441
[TBL] [Abstract][Full Text] [Related]
2. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials.
Schroen AT; Petroni GR; Wang H; Gray R; Wang XF; Cronin W; Sargent DJ; Benedetti J; Wickerham DL; Djulbegovic B; Slingluff CL
Clin Trials; 2010 Aug; 7(4):312-21. PubMed ID: 20595245
[TBL] [Abstract][Full Text] [Related]
3. Enrollment Trends Among Patients with Melanoma Brain Metastasis in Active Clinical Trials.
Elghawy O; Patel R; Xu J; Sussman J; Horton B; Kaur V
Cancer Invest; 2024 May; 42(5):400-407. PubMed ID: 38773947
[TBL] [Abstract][Full Text] [Related]
4. Good news about melanoma.
Elwood M; Rademaker M
N Z Med J; 2024 May; 137(1595):9-12. PubMed ID: 38754110
[No Abstract] [Full Text] [Related]
5. Correction to: MET receptor serves as a promising target in melanoma brain metastases.
Redmer T; Schumann E; Peters K; Weidemeier ME; Nowak S; Schroeder HWS; Vidal A; Radbruch H; Lehmann A; Kreuzer-Redmer S; Jürchott K; Radke J
Acta Neuropathol; 2024 Mar; 147(1):63. PubMed ID: 38536477
[No Abstract] [Full Text] [Related]
6. Achieving Exemplary Attributes With AccrualNet.
Baer AR; Hajovsky J; Zon R
J Oncol Pract; 2011 Nov; 7(6):e40-1. PubMed ID: 22379430
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab and whole brain radiation therapy for melanoma brain metastases.
Gerber NK; Young RJ; Barker CA; Wolchok JD; Chan TA; Yamada Y; Friguglietti L; Beal K
J Neurooncol; 2015 Jan; 121(1):159-65. PubMed ID: 25273687
[TBL] [Abstract][Full Text] [Related]
8. Whole-brain radiotherapy in patients with brain metastases from melanoma.
de la Fuente M; Beal K; Carvajal R; Kaley TJ
CNS Oncol; 2014 Nov; 3(6):401-6. PubMed ID: 25438811
[TBL] [Abstract][Full Text] [Related]
9. Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan.
Lo SN; Hong AM; Haydu LE; Ahmed T; Paton EJ; Steel V; Hruby G; Tran A; Morton RL; Nowak AK; Vardy JL; Drummond KJ; Dhillon HM; Mandel C; Scolyer RA; Middleton MR; Burmeister BH; Thompson JF; Fogarty GB
Trials; 2019 Aug; 20(1):477. PubMed ID: 31382986
[TBL] [Abstract][Full Text] [Related]
10. Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis.
Fuentes R; Osorio D; Expósito Hernandez J; Simancas-Racines D; Martinez-Zapata MJ; Bonfill Cosp X
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012086. PubMed ID: 30125049
[TBL] [Abstract][Full Text] [Related]
11. Quality assurance analysis of hippocampal avoidance in a melanoma whole brain radiotherapy randomized trial shows good compliance.
Martinage G; Hong AM; Fay M; Thachil T; Roos D; Williams N; Lo S; Fogarty G
Radiat Oncol; 2018 Jul; 13(1):132. PubMed ID: 30029684
[TBL] [Abstract][Full Text] [Related]
12. RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.
Gupta A; Roberts C; Tysoe F; Goff M; Nobes J; Lester J; Marshall E; Corner C; Wolstenholme V; Kelly C; Wise A; Collins L; Love S; Woodward M; Salisbury A; Middleton MR
Br J Cancer; 2016 Nov; 115(10):1193-1200. PubMed ID: 27711083
[TBL] [Abstract][Full Text] [Related]
13. Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial.
Kim MM; Parmar H; Cao Y; Pramanik P; Schipper M; Hayman J; Junck L; Mammoser A; Heth J; Carter CA; Oronsky A; Knox SJ; Caroen S; Oronsky B; Scicinski J; Lawrence TS; Lao CD
Transl Oncol; 2016 Apr; 9(2):108-113. PubMed ID: 27084426
[TBL] [Abstract][Full Text] [Related]
14. Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases.
Chowdhury IH; Ojerholm E; McMillan MT; Miller D; Kolker JD; Kurtz G; Dorsey JF; Nagda SN; Geiger GA; Brem S; O'Rourke DM; Zager EL; Gangadhar T; Schuchter L; Lee JY; Alonso-Basanta M
Radiat Oncol; 2015 Dec; 10():248. PubMed ID: 26626714
[TBL] [Abstract][Full Text] [Related]
15. Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review.
Goyal S; Silk AW; Tian S; Mehnert J; Danish S; Ranjan S; Kaufman HL
JAMA Oncol; 2015 Aug; 1(5):668-76. PubMed ID: 26181286
[TBL] [Abstract][Full Text] [Related]
16. First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality.
Fogarty GB; Hong A; Dolven-Jacobsen K; Reisse CH; Burmeister B; Haydu LH; Dhillon H; Steel V; Shivalingam B; Drummond K; Vardy J; Nowak A; Hruby G; Scolyer RA; Mandel C; Thompson JF
BMC Res Notes; 2015 May; 8():192. PubMed ID: 25952979
[TBL] [Abstract][Full Text] [Related]
17. Accrual to a randomised trial of adjuvant whole brain radiotherapy for treatment of melanoma brain metastases is feasible.
Fogarty GB; Hong A; Jacobsen KD; Reisse CH; Shivalingam B; Burmeister B; Haydu LE; Paton E; Thompson JF
BMC Res Notes; 2014 Jun; 7():412. PubMed ID: 24981506
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
